Evidence map›Paper›PMID 39286329›Full record

ArticleIn silico pharmacology2024

Discovery, lead identification and exploration of potential oxadiazole derivatives in targeting STAT3 as anti-cancer agents.

Vivek Panwar, Sounok SenGupta, Saroj Kumar, Praveen P Singh, Arun Kumar, Shavkatjon Azizov, Manoj K Gupta, Deepak Kumar

Abstract read
In one paragraph

Article in In silico pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Unraveling bioactive potential and production inChinese herbal medicines · 2025
    Review
  2. Design, synthesis,Future medicinal chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vivek PanwarDepartment of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Himachal Pradesh, Solan, 173229 India.
Sounok SenGuptaDepartment of Pharmacology, School of Pharmaceutical Sciences, Shoolini University, Himachal Pradesh, Solan, 173229 India.
Saroj KumarDepartment of Biophysics, All India Institute of Medical Sciences, New Delhi, 110029 India.
Praveen P SinghDepartment of Chemistry, United College of Engineering & Research, Prayagraj, 211010 India.
Arun KumarMahavir Cancer Sansthan & Research Centre, Patna, Bihar- 801505 India.
Shavkatjon AzizovLaboratory of Biological Active Macromolecular Systems, Institute of Bioorganic Chemistry, Academy of Sciences Uzbekistan, 100125 Tashkent, Uzbekistan.
Manoj K GuptaDepartment of Chemistry, Central University of Haryana, Mahendergarh, 123031 Haryana India.
Deepak KumarDepartment of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Himachal Pradesh, Solan, 173229 India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxadiazoles an important heterocyclic scaffold of medicinal importance in the field of drug discovery. In the study, a library of oxadiazole based compounds was selected for screening against STAT-3 as anti-cancer target. STAT3 is a potential target of interest in cancer therapy. A total of 544 screened library of compounds was subjected to molecular docking against STAT-3 (6NJS and 6NQU). The compounds with good dock score and binding interations were further subjected to in-silico ADME analysis followed by toxicity estimation. A total of 141 hits were selected against 6NJS and 50 hits against 6NQU and further screened for kinetic properties and drug likeliness. The compounds were screened on the basis of physico-chemical properties, solubility, gastrointestinal absorption, BBB permeability, synthetic accessibility, Lipinski and other violations. Best compounds obtained after ADME analysis were further subjected for toxicity analysis. Carcinogenecity, mutagenicity, Ames and other important parameters were considered for toxicity based screening. The best leads thus obtained (compound 114 and 40) were further subjected to molecular dynamics against the respective target proteins. MD simulations were run to access the stability of C-114 and C-40 along with the dynamic behaviour of both complexes for about 100 ns and shows good stability with the proteins.

Indexed as

Anticancer compoundsDrug discoveryKinasesOxadiazole derivativesSTAT3

Identifiers

PMID39286329
PMCPMC11401806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.